Martin Shkreli
Business Executive

Martin Shkreli Net Worth

Martin Shkreli, born in Brooklyn, NY in 1983, is a controversial figure in the pharmaceutical industry. He is the founder and former CEO of Turing Pharmaceuticals, and is known for raising the price of the drug Daraprim from $13.50 per pill to $750, a drug the World Health Organization lists as an essential medicine. He also founded MSMB Capital Management and Retrophin LLC, the latter of which sued him for $65 million.
Martin Shkreli is a member of Business Executive

Age, Biography and Wiki

Birth Day April 1, 1983
Birth Place Brooklyn, NY
Age 40 YEARS OLD
Birth Sign Aries

💰 Net worth: $27.1 million (2024)

About

Founder and former CEO of Turing Pharmaceutical who's known for raising the price of the drug Daraprim from $13.50 per pill to $750, a drug the World Health Organization lists as an essential Medicine. He also founded MSMB Capital Management and Retrophin LLC, the latter of which would later sue him for $65 million.

Before Fame

He attended Hunter College High School and started interning for Cramer Berkowitz & Co. when he was 17. He graduated from Baruch College in 2004 and founded his first hedge fund in 2006.

Trivia

Bloomberg described him as both embodying the American dream and sullying it. He was arrested in late 2015 on charges of securities fraud. He bought the only copy of the Wu Tang Clan's album Once Upon a Time in Shaolin.

Family Life

He was born to Albanian and Croatian immigrants. He grew up with two sisters and a brother.

Associated With

Bernie Sanders, Hillary Clinton, and Donald Trump were among those who criticized the decision to increase the price of Daraprim.

Some Martin Shkreli images

About the author

Lisa Scholfield

As a Senior Writer at Famous Net Worth, I spearhead an exceptional team dedicated to uncovering and sharing the stories of pioneering individuals. My passion for unearthing untold narratives drives me to delve deep into the essence of each subject, bringing forth a unique blend of factual accuracy and narrative allure. In orchestrating the editorial workflow, I am deeply involved in every step—from initial research to the final touches of publishing, ensuring each biography not only informs but also engages and inspires our readership.